**Expedited Partner Therapy for Chlamydia**

**Patient-delivered partner treatment to prevent reinfection**

**Chlamydia trachomatis (chlamydia)** is the most frequently reported infectious disease in the United States and in New York City (NYC). The number of reported cases of chlamydial infection in NYC is increasing: in 2015, there were 62,965 cases, a 53% increase from 2006.

Chlamydia is a leading cause of infertility, pelvic inflammatory disease (PID), chronic pelvic pain, and ectopic pregnancy. Repeated chlamydial infections are common, and each reinfection increases the risk of these serious sequelae. Having an untreated sex partner is an important risk factor for reinfection, so treating the partners of individuals diagnosed with chlamydia is critical to preventing these outcomes.
Expedited partner therapy (EPT) is an innovative, evidence-based tool that health care providers can use along with other partner management strategies. With EPT, an index patient diagnosed with chlamydia receives prescriptions or medications to take to his/her partners. The partners do not need to be examined by a health care provider to receive treatment.

EPT decreases rates of chlamydial reinfection among index patients and increases the proportion of partners receiving treatment for chlamydia. EPT also helps interrupt the ongoing transmission of chlamydia.

EPT has been available in other states for approximately 15 years; in California, where an EPT hotline was maintained, there were no adverse events and/or life-threatening allergic reactions reported (Heidi Bauer, MD, written communication, 2011).

Who Is Eligible for EPT?

EPT may be given to patients of any age with a chlamydia diagnosis and should be provided for partners with whom the index patient had sex in the 60 days prior to his or her treatment for chlamydia (or for the most recent partner if the index patient had none in the previous 60 days).
Caveats:

- **EPT may not** be given if the index patient is coinfected with gonorrhea or syphilis because the medication used does not adequately treat gonorrhea or syphilis. Coinfected partners could be mistakenly reassured by treatment and not seek care for these other infections.

- **EPT should not** be given if it would put the index patient’s or partner’s safety at increased risk, for example, where intimate partner violence or sexual abuse is suspected.

- **EPT is not** recommended for men who have sex with men due to the lack of data on the effectiveness of this strategy in that population and the increased risk that the partner may be coinfected with other STIs, including HIV.

The recommended EPT treatment is azithromycin, 1 gram in a single oral dose. Doxycycline is not recommended for EPT due to lack of data. Efficacy studies of EPT have all used single-dose therapy and treating chlamydia with doxycycline requires a 7-day regimen. The names of partners should not be written in the index patient’s medical record to prevent inadvertent release of partners’ health information.

Prescribing: For detailed information on how to prescribe EPT and how EPT prescriptions may be filled, see Box, page 4.

Dispensing: Some medical offices may choose to dispense medication for partners at no cost instead of writing a prescription; this can help to ensure confidentiality and remove cost barriers, especially for adolescents.

If an index patient suggests that a partner is allergic to azithromycin, erythromycin, clarithromycin, or any macrolide or ketolide, providers should not dispense azithromycin or write a prescription for it. That partner should instead seek clinical evaluation.

For more information on EPT or a related medical consult, contact the NYC Health Department at 1-866-NYC-DOH1 (1-866-692-3641)
EPT PRESCRIBING AND FILLING

The New York State Commissioner of Health has waived the electronic prescribing mandate in situations requiring the use of EPT. Providers can continue to use paper prescriptions for the treatment of sex partner(s) of patients infected with chlamydia until at least March 26, 2017.

Prescriptions must include:

- Name and address of the prescribing provider and date issued;
- The initials EPT in the body of the prescription form, above the name and dosage of the medication;
- Directions for the use of the drug by the patient (ie, azithromycin, 1 gram taken in a single oral dose);
- The name, address, and date of birth of the partner if available. If the partner’s name, address, and date of birth are not available, the designated areas may be left blank.

A separate prescription must be provided for each partner:

- Providers should not prescribe treatment for a partner by writing extra doses of medication on an index patient’s prescription.

Liability: Health care providers or pharmacists who prescribe or dispense drugs in accordance with the EPT law and regulations will not be held legally or professionally liable.⁶

Payment for the medication: Medication may be paid for by the person who picks up the prescription or by the partner’s health insurance. Pharmacists should not bill the partner’s prescription under the index patient’s name. Some medical offices may choose to dispense medications for partners at no cost instead of writing a prescription to remove cost barriers and to ensure confidentiality, especially for adolescents.

If the partner is allergic to azithromycin: EPT should not be used to treat a partner who is known to be allergic to azithromycin, erythromycin, clarithromycin, or any macrolide or ketolide. The partner should be instructed to see a physician for evaluation and appropriate treatment.

Potential drug interactions with azithromycin: If the index patient suggests a partner is at risk for a possible drug interaction with azithromycin, EPT should not be dispensed. The partner should be referred to a physician or emergency room for appropriate treatment.

Record-keeping for EPT prescriptions: EPT prescriptions should be filed like prescriptions for any noncontrolled substances.
Whether dispensing medication or writing prescriptions, NYS EPT regulations require that providers give the index patient health education materials (Resources) to be delivered to the partner(s) that:

- Encourage the partner(s) to seek evaluation for STIs from a health care provider as a preferred alternative to EPT, whether or not they take the medication;
- Explain the risk of potential adverse drug reactions, including allergic reactions and interactions with other medications;
- Tell the partner that he or she may be affected by other STIs that the prescribed medicine may not treat;
- Encourage partners, especially the following, to seek medical care as soon as possible:
  - Pregnant partners
  - Partners who have symptoms of a more serious infection (eg, abdominal, pelvic, or testicular pain, fever, nausea, or vomiting)
  - Partners at high risk for HIV infection;
  - Instruct the index patient and the partner to abstain from all sexual activity for at least 7 days after both the index patient and the partner are treated to decrease the risk of chlamydial reinfection;
- Inform the index patient and the partner how to prevent chlamydial reinfection.

The NYC Health Department can provide you with patient and partner materials in English and Spanish. Go to www.nyc.gov/health/ept.

After EPT: Three months after treatment, retest the index patient for chlamydia to rule out reinfection.1

Index patients who prefer not to give EPT to their partners can notify them of exposure to an STI anonymously through an online service called inSPOTNYC.

inSPOTNYC

The inSPOT Web site, www.inspot.org/newyorkcity, allows New York City residents to send anonymous e-cards to their partners, telling them that they have been exposed to STIs, including HIV. E-card recipients can click on the link to find information on STIs and search for a convenient testing site.
Health care providers diagnosing chlamydia and laboratories detecting chlamydia in submitted specimens from New York City residents are legally obligated to report cases to the New York City Department of Health and Mental Hygiene.  

Report all chlamydia cases through the Universal Reporting Form, available online at [www1.nyc.gov/site/doh/providers/reporting-and-services/reporting-central.page](http://www1.nyc.gov/site/doh/providers/reporting-and-services/reporting-central.page) or by calling 1-866-NYC-DOH1 (1-866-692-3641). When reporting, specify whether EPT was used to treat the partners of the reported case, and if so, the number of partners for whom medication was dispensed or prescriptions written. Partner names are not necessary.

### Resources

For more information on EPT or a related medical consult, contact the NYC Health Department at **1-866-NYC-DOH1 (1-866-692-3641)**.

New York City Department of Health and Mental Hygiene:

- **EPT Program:** [www.nyc.gov/health/ept](http://www.nyc.gov/health/ept)
- **Materials for Patients, Partners, Pharmacists, and Health Care Providers**
- **New York State EPT Law and Regulations**
- **Chlamydia Web page:** [www1.nyc.gov/site/doh/health/health-topics/chlamydia.page](http://www1.nyc.gov/site/doh/health/health-topics/chlamydia.page)
- **Adverse Events Reporting:** Providers: To report an adverse event related to EPT, call the provider access line: **1-866-NYC-DOH1 (1-866-692-3641)**

- **New York City STD clinics:** [www1.nyc.gov/site/doh/services/clinics.page](http://www1.nyc.gov/site/doh/services/clinics.page)


References


8. New York City Health Code §11.03 and 13.03.